Last reviewed · How we verify
NCT05663450
Extended Resection After Positive Intraoperative Pathology in Gastric Cancer Surgery
trial in Gastric Cancer in 679 participants. Completed in 31 March 2022.
31 December 2019
Quick facts
| Lead sponsor | University Hospital of Cologne |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 679 |
| Start date | 1 May 1996 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 March 2022 |
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
University Hospital of Cologne
Who can join
Adults 59 to 66, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Of 737 consecutive patients undergoing (sub)total gastrectomy for gastric or GEJ adenocarcinoma, 679 cases with curative intent surgery between 05/1996 and 03/2019 were included. Patients were categorized into: i) R0 without further resection (direct R0), ii) R0 after positive IOC and extension of resection (converted R0) and iii) R1.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Extension of resection after positive intraoperative pathology during surgery for gastric and gastroesophageal junction adenocarcinoma: a retrospective cohort study.
Plum PS, Barutcu AG, Pamuk A, Mallmann C, et al · · 2023 · PMID 37222663 · DOI 10.1097/js9.0000000000000484
Verify or expand the search:
- PubMed search for NCT05663450
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other University Hospital of Cologne trials
Trials by the same sponsor.
- NCT07389746 — Preoperative Physical Exercise, Nutritional Support, and Psychological Intervention (Multimodal Prehabilitation) to Stre · NA · not yet recruiting
- NCT07490912 — Neonatal Data and Biobank to Study Factors Influencing Development in Preterm Infants Born at <32 Weeks' Gestation and/o · recruiting
- NCT06729645 — External Beam Radiotherapy Combined with Endorectal High-dose-rate Brachytherapy in Elderly and Frail Patients with Rect · NA · not yet recruiting
- NCT06535022 — DeliKet (Substudy of KetoNiFast Study ID 22-1398_1) · NA · not yet recruiting
- NCT06497322 — Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05663450 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital of Cologne
- Last refreshed: 23 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05663450.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing